

**REMARKS**Interview

Applicants would like to thank Examiner Phuong Huynh for the phone conference held with Applicants' representative on May 1, 2008. During the phone interview, the Examiner proposed amendments to the claims for overcoming the rejections. Applicants have considered the proposed amendments and have incorporated some of the proposed amendments into the claims.

Status of the Claims

Claims 44-66 are currently pending. Claims 1-43 have been canceled without prejudice or disclaimer of the subject matter claimed therein.

New claims 44-53 are directed to the same invention as 15-25 and 40-43. New claims 54-66 are directed to methods of using the antibody of claim 44 and are directly or indirectly dependent upon claim 44. New claims 54-66 are withdrawn from consideration as being directed to a separate invention.

Support for the new claims can be found throughout the specification, especially in the claims. Representative support is summarized in the table below.

Claim(s)	Representative Support
44, 52	Claim 22, Page 3, lines 22-24
45	Claim 17
46	Claim 18
47	Claim 19
48	Claim 21
50	Claim 22
51	Claim 23
53	Claims 42, 43
54	Claim 26
55	Claim 27
56	Claim 28

57	Claim 29
58	Claim 30
59	Claim 31
60	Claim 32
61	Claim 33
62	Claim 34
63	Claim 35
64	Claim 36
65	Claim 37
66	Claim 38

New claims 44-66 do not introduce prohibited new matter.

#### Rejoinder

New claims 54-66, directed to methods of using the antibody of claim 44, are withdrawn from consideration as being directed to a separate invention.

Applicant respectfully points out that MPEP 821.04(b) requires that once a product claim is found allowable, withdrawn method claims which depend from or otherwise include all the limitations of the allowable product claim must be rejoined. Thus, once a claim directed to the antibody (44-49) is found allowable, withdrawn method claims (54-66) which depend from or otherwise include all the limitations of the allowed claim must be rejoined.

#### Objection

Claim 15 has been objected to because it is unclear. Claim 15 has been canceled and replaced with claim 44.

#### Rejections under 35 U.S.C. § 102(b)

A. Claims 15 and 18 are rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 5,766,860 ('860)

Claims 15 and 18 have been canceled. This rejection is not applicable to the new claims because '860 neither teaches nor suggests the claimed invention.

B. Claims 15, 17-19, and 21-23 are rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 6,204,011 ('011).

Claims 15, 17-19, and 21-23 have been canceled. This rejection is not applicable to the new claims because '011 neither teaches nor suggests the claimed invention.

C. Claims 15, 17-19, 22-23, and 40 are rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent 5,840,301 ('301).

Claims 15, 17-19, 22-23, and 40 have been canceled. This rejection is not applicable to the new claims because '301 neither teaches nor suggests the claimed invention.

Rejections under 35 U.S.C. § 103(a)

A. Claims 15, 17-19, 22-25, 42, and 43 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Takahashi *et al.* (Takahashi) in view of Harlow *et al.* (Harlow).

Claims 15, 17-19, 22-25, 42, and 43 have been canceled.

This rejection is not applicable to new claims 44-53 because Takahashi does not disclose or suggest the claimed invention. Takahashi neither discloses the claimed antibodies nor provides methods for generating the claimed antibodies. Takahashi also does not disclose the peptides used in generating the claimed antibodies.

Harlow does not cure the deficiencies of Takahashi because Harlow neither discloses the claimed antibodies nor provides methods for generating the claimed antibodies. Moreover, Harlow does not disclose the peptides used in generating the claimed antibodies.

Accordingly, there is no reason to combine the teachings of the cited references and to modify the teachings to arrive at the claimed invention with reasonable expectation of success. Thus, the cited references do not render the claimed invention obvious.

B. Claim 21 is rejected under 35 U.S.C. § 103(a) as being unpatentable over Takahashi *et al.* (Takahashi) in view of Harlow *et al.* (Harlow) as applied to claims 15, 17-19, 22-25, and 42-43 and further in view of U.S. Patent 6,204,011 ('011).

Claim 21 has been canceled. For the reasons discussed above, Takahashi and Harlow are not applicable to new claims 44-53. '011 is also not applicable to the new claims because '011 does not disclose or suggest the claimed invention and does not cure the deficiencies of Takahashi and Harlow.

C. Claim 40 is rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent 6,204,011 ('011) in view of Harlow *et al.* (Harlow).

Claim 40 has been canceled. For the reasons discussed above, '011 and Harlow are not applicable to the new claims because '011 does not teach or suggest the claimed invention and Harlow does not cure the deficiencies of '011.


### Conclusion

The foregoing amendments and remarks are being made to place the application in condition for allowance. Applicants respectfully request entry of the amendments, reconsideration, and the timely allowance of the pending claims. A favorable action is awaited. Should an interview be helpful to further prosecution of this application, the Examiner is invited to telephone the undersigned.

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. §1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

Date: June 4, 2008  
Morgan, Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel: 202-739-3000  
Fax: 202-739-3001

  
Sally P. Teng, Ph.D.  
Registration No. 45,397